Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19

We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunct...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghavi, Devang K., Titus, Anoop, Caulfield, Thomas R., David Freeman, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985609/
https://www.ncbi.nlm.nih.gov/pubmed/33823371
http://dx.doi.org/10.1016/j.mehy.2021.110564
_version_ 1783668283901214720
author Sanghavi, Devang K.
Titus, Anoop
Caulfield, Thomas R.
David Freeman, W.
author_facet Sanghavi, Devang K.
Titus, Anoop
Caulfield, Thomas R.
David Freeman, W.
author_sort Sanghavi, Devang K.
collection PubMed
description We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.
format Online
Article
Text
id pubmed-7985609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-79856092021-03-23 Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19 Sanghavi, Devang K. Titus, Anoop Caulfield, Thomas R. David Freeman, W. Med Hypotheses Article We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease. Elsevier Ltd. 2021-05 2021-03-23 /pmc/articles/PMC7985609/ /pubmed/33823371 http://dx.doi.org/10.1016/j.mehy.2021.110564 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sanghavi, Devang K.
Titus, Anoop
Caulfield, Thomas R.
David Freeman, W.
Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title_full Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title_fullStr Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title_full_unstemmed Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title_short Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
title_sort endotheliitis, endothelin, and endothelin receptor blockers in covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985609/
https://www.ncbi.nlm.nih.gov/pubmed/33823371
http://dx.doi.org/10.1016/j.mehy.2021.110564
work_keys_str_mv AT sanghavidevangk endotheliitisendothelinandendothelinreceptorblockersincovid19
AT titusanoop endotheliitisendothelinandendothelinreceptorblockersincovid19
AT caulfieldthomasr endotheliitisendothelinandendothelinreceptorblockersincovid19
AT davidfreemanw endotheliitisendothelinandendothelinreceptorblockersincovid19

Ejemplares similares